Poster Abstracts
Grand Hall CD (Manchester Grand Hyatt)
Factors Influencing Pulmonary Toxicity in the Setting of Total Body Irradiation-Based Myeloablative Conditioning in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Mustafa Abugideiri, BS, The George Washington University School of Medicine and Health Sciences;
Ronica H. Nanda, MD, Emory University, Winship Cancer Institute;
Charlotte Butker, Emory University;
Sungjin Kim, PhD, Emory University, Winship Cancer Institute;
Elizabeth Butker, MS, Emory University, Winship Cancer Institute;
Mohammad K. Khan, MD, PhD, Emory University, Winship Cancer Institute;
Natia Esiashvili, MD, Emory University, Winship Cancer Institute
Encouraging Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation - Single Centre Experience from Resource Poor Country
Rayaz Ahmed, DM, Rajiv Gandhi Cancer and Research Center;
Narendra Agrawal, DM, Rajiv Gandhi Cancer Institute and Research Centre;
Anshul Gupta, MD, Rajiv Gandhi Cancer Institute and Research Centre;
Jyotsna Kapoor, MSc, Rajiv Gandhi Cancer Institute and Research Centre;
Dinesh Bhurani, DM, Rajiv Gandhi Cancer and Research Center
Plasma IL-7 and IL-15 Levels Vary Greatly after Low-Intensity Conditioning and May be Associated with Clinical Outcome in Recipients of High-Dose Sirolimus Gvhd Prophylaxis
Syed Abbas Ali, MD, National Cancer Institute, National Institutes of Health;
Seth M. Steinberg, PhD, Center for Cancer Research, National Cancer Institute, National Institutes of Health;
Miriam Mossoba, PhD, NCI;
Joseph Rimando, National Institutes of Health;
Scott Rowley, MD, Hackensack University Medical Center;
Michele L. Donato, MD, Hackensack University Medical Center;
Kevin Camphausen, MD, Center for Cancer Research, National Cancer Institute, NIH;
George Sigal, Meso Scale Diagnostics;
Fran Hakim, PhD, National Cancer Institute, National Institutes of Health;
Ronald Gress, MD, * Co-Senior Experimental Transplantation and Immunology Branch/NCI/NIH;
David Halverson, MD, NCI;
Daniel Fowler, MD, National Cancer Institute, National Institutes of Health
Immunogenetic Cross-Talk in Patients Transplanted for AML: CMV Reactivation Is Not a Strong Stimulus for Immune Response Against Leukemia
Apostolia Papalexandri, George Papanicolaou Hospital;
Ioanna Sakellari, George Papanicolaou Hospital;
Chrysa Apostolou, George Papanicolaou Hospital;
Zoi Boussiou, George Papanicolaou Hospital;
Damianos Sotiropoulos, George Papanicolaou Hospital;
Sofia Charalampidou, George Papanicolaou Hospital;
Panayiota Zerva, George Papanicolaou Hospital;
Tasoula Touloumenidou, George Papanicolaou Hospital;
Varnavas Konstantinou, George Papanicolaou Hospital;
Despina Mallouri, George Papanicolaou Hospital;
Ioannis Batsis, George Papanicolaou Hospital;
Achilles Anagnostopoulos, MD, George Papanicolaou Hospital
Blood Stream Infection Is Frequent during Conditioning but Does Not Impact Allogeneic Transplant Outcomes in the Modern Era
Prathima Anandi, MD, National Heart, Lung, and Blood Institute, NIH;
Neil Dunavin, MD, National Heart, Lung, and Blood Institute, NIH;
Natasha A Jain, MD, National Heart, Lung, and Blood Institute, NIH;
Puja D Chokshi, MD, National Heart, Lung, and Blood Institute, NIH;
Ankit Anand, MD, National Heart, Lung, and Blood Institute, NIH;
Robert Q Le, MD, Phd, National Heart, Lung, and Blood Institute, NIH;
Sawa Ito, MD, National Heart, Lung, and Blood Institute, NIH;
A. John Barrett, MD, National Heart, Lung, and Blood Institute, NIH;
Minoo Battiwalla, MD, MS, National Heart, Lung, and Blood Institute, NIH
Adult Patients with Acute Lymphoblastic Leukemia (ALL) with Induction Failure or after Relapse: Cure By Allogeneic Stem Cell Transplantation (SCT), but High Risk of Relapse
Renate Arnold, MD, Charité - Universitätsmedizin Berlin;
Theis Terwey, MD, Charité - Universitätsmedizin Berlin;
Il-Kang Na, MD, Charité - Universitätsmedizin Berlin;
Gero Massenkeil, MD, Klinikum Gütersloh;
Olaf Penack, MD, Charité - Universitätsmedizin Berlin;
Lam Vuong, PhD, Charité - Universitätsmedizin Berlin;
Christian Jehn, MD, Charité - Universitätsmedizin Berlin;
Hendrik Nogai, MD, Charité - Universitätsmedizin Berlin;
Philipp Hemmati, MD, Charité - Universitätsmedizin Berlin
The Use of a Reduced-Intensity Conditioning (RIC) Regimen in Patients Ages 2-30 Undergoing Allogeneic Transplantation for Sickle Cell Disease
Suhrad Banugaria, MD, New Jersey Medical School, Rutgers University;
Alfred P. Gillio, MD, Hackensack University Medical Center;
Jeanette Haugh, RN, APN, CCRC, Hackensack University Medical Center;
Nancy Durning, APN, CBMT, Hackensack University Medical Center;
Melanie Nycz, APN, CPHON, CPNP-PC, Hackensack University Medical Center;
Barbara Adler-Brecher, MS, Hackensack University Medical Center;
Jennifer Krajewski, MD, Hackensack University Medical Center
Pre-Transplant Consolidation Chemotherapy for Acute Lymphocytic Leukemia (ALL) Does Not Impact Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT)
Nelli Bejanyan, MD, University of Minnesota Medical Center;
Aleksandr Lazaryan, MD MPH PhD, University of Minnesota Medical Center;
Ryan Shanley, M.S., University of Minnesota Medical Center;
Sagar Patel, M.D., University of Minnesota Medical School;
Claudio G. Brunstein, MD, PhD, University of Minnesota Medical Center;
Veronika Bachanova, MD, University of Minnesota Medical Center
A Proven and Probable Case of Pre-Existing IgA Nephropathy Exacerbated By Administration of G-CSF
Annelies Billen, UCL Cancer Institute;
Jasmin B.L. Lee, Department of Renal Medicine, King's College London;
Robert Lown, Anthony Nolan;
Michael Potter, Royal Marsden Hospital;
Charles Craddock, Queen Elizabeth Hospital;
Hugues de Lavallade, Department of Haematology, King's College Hospital, London;
Bronwen E. Shaw, MD, PhD, CIBMTR and Medical College of Wisconsin;
Claire Sharpe, Department of Renal Medicine, King's College Hospital London;
David Kipgen, Department of Pathology, Southern General Hospital, Glasgow
Comparison of Haploidentical T-Replete HSCT Followed with Post-Transplant
High Dose Cyclophosphamide (PT-HDCy) with Matched Related (MRD) or Unrelated (UD) HSCT in Patients in or after the 6TH Decade
Didier Blaise, MD, Institut Paoli Calmettes;
Sabine Furst, MD, Institut Paoli Calmettes;
Jean El Cheikh, Institut Paoli Calmettes;
Roberto Crocchiolo, Institut Paoli-Calmettes;
Raynier Devillier, Institut Paoli Calmettes;
Stephania Bramanti, Humanitas;
Angela Granata, Institut Paoli-Calmettes;
Samia Harbi, Institut Paoli Calmettes;
Réda Bouabdallah, Institut Paoli-Calmettes;
Bilal Mohty, Institut Paoli Calmettes;
Claude Lemarie, Institut Paoli Calmettes;
Christian Chabannon, MD, PhD, Institut Paoli Calmettes;
Catherine Faucher, Institut Paoli Calmettes;
Norbert Vey, Institut Paoli-Calmettes;
Luca Castagna, Institut Paoli-Calmettes
Presentation and Outcome of Zap 70 Deficiency
Rae Brager, MD, Hospital for Sick Children;
Alison Haynes, MD, Hospital for Sick Children;
Eyal Grunebaum, MD, Hospital for Sick Children;
Manfred Hoenig, MD, Universitätsklinik für Kinder- und Jugendmedizin;
Hamoud Al-Mousa, MD, King Faisal Specialist Hospital & Research Center;
Waleed Al-Herz, MD, Pediatrics Department, Faculty of Medicine, Kuwait University;
Neena Kapoor, MD, Children's Hospital Los Angeles;
Chaim Roifman, The Hospital for Sick Children
A Multicenter Phase I/II Study of Relapse Prophylaxis with Nilotinib after Hematopoietic Cell Transplantation (HCT) for High-Risk Philadelphia Chromosome-Positive (Ph+) Leukemias
Paul A. Carpenter, MD, Fred Hutchinson Cancer Research Center;
Laura Johnston, MD, Stanford University Medical Center;
Hugo Fernandez, MD, H. Lee Moffitt Cancer Center and Research Institute;
Jerald Radich, MD, Fred Hutchinson Cancer Research Center;
Michael J Mauro, MD, Oregon Health Sciences University;
Mary E. D. Flowers, MD, Fred Hutchinson Cancer Research Center;
Paul J. Martin, MD, Fred Hutchinson Cancer Research Center;
Ted Gooley, PhD, Fred Hutchinson Cancer Research Center
Minor ABO Incompatibility Does Not Impact Non-Relapse Mortality in T-Cell Depleted HLA-Matched Sibling Transplantation
Puja D Chokshi, MD, National Heart, Lung, and Blood Institute, NIH;
Prathima Anandi, MD, National Heart, Lung, and Blood Institute, NIH;
Natasha A Jain, MD, National Heart, Lung, and Blood Institute, NIH;
Neil Dunavin, MD, National Heart, Lung, and Blood Institute, NIH;
Robert Q Le, MD, Phd, National Heart, Lung, and Blood Institute, NIH;
Sawa Ito, MD, National Heart, Lung, and Blood Institute, NIH;
A. John Barrett, MD, National Heart, Lung, and Blood Institute, NIH;
Minoo Battiwalla, MD, MS, National Heart, Lung, and Blood Institute, NIH
Impact of Daptomycin Minimum Inhibitory Concentration (MIC) on Outcomes of Patients with Hematologic Malignancies and Hematopoietic Stem Cell Transplant (HSCT) Recipients with Vancomycin-Resistant Enterococci (VRE) Bloodstream Infection (BSI)
Pearlie P. Chong, MD, University of North Carolina at Chapel Hill;
David van Duin, MD, PhD, University of North Carolina at Chapel Hill;
Ananta Bangdiwala, University of North Carolina at Chapel Hill;
Anastasia Ivanova, PhD, University of North Carolina at Chapel Hill;
Alan Kerr, University of North Carolina Hospitals;
David J. Weber, MD, MPH, University of North Carolina at Chapel Hill;
Peter H. Gilligan, PhD, University of North Carolina at Chapel Hill;
Tippu Khan, PharmD, University of North Carolina;
Thomas C. Shea, MD, University of North Carolina at Chapel Hill
ALPHA/Beta T- CELL Depleted Allogeneic STEM CELL Transplantation from Matched Related and Unrelated DONOR Grafts in Patients with Poor Risk Leukemia
Moniek de Witte, MD, PhD, University Medical Center Utrecht;
Lotte van der Wagen, MD, University Medical Center Utrecht;
Ineke Slaper-Cortenbach, PhD, UMC Utrecht;
Jurgen Kuball, MD, PhD, University Medical Center Utrecht
Outcomes of Allogeneic Hematopoietic Cell Transplantation (AHCT) for Multiple Myeloma (MM): Impact of Disease Risk and Conditioning Regimen
Binod Dhakal, MD, Medical College of Wisconsin;
Michael Martens, PhD, Medical College of Wisconsin;
Jonathan Kapke, MD, Medical College of Wisconsin;
Anita D'Souza, MD, Medical College of Wisconsin;
Marcelo C. Pasquini, MD, MS, CIBMTR and Medical College of Wisconsin;
Wael Saber, MD, MS, Medical College of Wisconsin;
Mehdi Hamadani, MD, West Virginia University - Mary Babb Randolph Cancer Center;
William Drobyski, MD, Medical College of Wisconsin;
J. Douglas Rizzo, MD, MS, CIBMTR and Medical College of Wisconsin;
Mary M. Horowitz, MD, MS, CIBMTR and Medical College of Wisconsin;
Mei-Jie Zhang, PhD, Medical College of Wisconsin;
Parameswaran N. Hari, MD, MS, CIBMTR/Medical College of Wisconsin
The Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Elderly Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in the Era of Tyrosine Kinase Inhibitor (TKI) : A Single Institute Experience
Noriko Doki, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital;
Aiko Igarashi, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital;
Yuho Najima, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital;
Takeshi Kobayashi, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital;
Kazuhiko Kakihana, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital;
Hisashi Sakamaki, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital;
Kazuteru Ohashi, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
Prevalence of Vitamin D Deficiency in Allogeneic HCT Recipients and Its Association with Graft Versus Host Disease
Linda Dupuis Rosen, RN, OCN, Stanford University Medical Center- Stanford Health Care;
Tara Coghlin Dickson, MS, RD, CSSD, Stanford University Medical Center- Stanford Health Care;
Kate Tierney, PhD, Stanford University Medical Center;
Laura Johnston, MD, Stanford University Medical Center;
David Pickham, RN, PhD, Stanford University Medical Center- Stanford Health Care
Phenotype, Function and Expansion of Regulatory T Cells in the Cynomolgus Macaque (Macaca fascicularis)
Paula Alonso Guallart, D.V.M., Columbia University;
Jonah Zitsman, Columbia University;
Hugo Sondermeijer, M.D. M.S., Columbia University;
Leo Bühler, M.D., Massachusetts General Hospital;
Christopher Ovanez, M.D., Columbia University;
Alicia McMurchy, Ph.D., The University of British Columbia;
Megan Levings, Ph.D., The University of British Columbia | Child and Family Research Institute;
Megan Sykes, MD, Columbia University;
Raimon Duran-Struuck, D.V.M. Ph.D. DACLAM, Columbia University
High Rates of Early Donor Chimerism in Intermediate and Poor Risk Patients Undergoing Stem Cell Transplantation Using Reduced Toxicity Ablative Conditioning Regimen Incorporating Busulfan Pharmacokinetics
Shatha Farhan, M.D., Henry Ford Hospital;
Edward Peres, M.D., Henry Ford Hospital;
Danielle Pelland, Henry Ford Hospital;
Susan Wautelet, Henry Ford Hospital;
Klodiana Neme, PharmD, Henry Ford Hospital;
Nancy Mikulandric, PharmD, Henry Ford Hospital;
Kenneth Ruemenapp, Henry Ford Hospital;
Mary Ann Trapp, Henry Ford Hospital;
Sarah Szymanski, Henry Ford hospital;
Nalini Janakiraman, M.D., Henry Ford Hospital
Impact of Gender: Female Matched Related Donor Versus Male Matched Unrelated Donor on Peripheral Blood Allogeneic Stem Cell Transplant for Male Recipients
Shatha Farhan, M.D., Henry Ford Hospital;
Edward Peres, M.D., Henry Ford Hospital;
Danielle Pelland, Henry Ford Hospital;
Susan Wautelet, Henry Ford Hospital;
Klodiana Neme, PharmD, Henry Ford Hospital;
Nancy Mikulandric, PharmD, Henry Ford Hospital;
Kenneth Ruemenapp, Henry Ford Hospital;
Mary Ann Trapp, Henry Ford Hospital;
Sarah Szymanski, Henry Ford hospital;
Nalini Janakiraman, M.D., Henry Ford Hospital
Ruxolitinib Prior to Allogeneic Stem Cell Transplant: The Experience at Mayo Clinic Arizona
Veena Fauble, MD, Banner/MD Anderson Blood & Marrow Transplant Program;
Pierre Noel, MD, Mayo Clinic Arizona;
Ruben A. Mesa, MD, FACP, Mayo Clinic Arizona;
Roberta Adams, MD, Mayo Hospital;
Jose Leis, MD, PhD, Mayo Clinic Arizona;
Nandita Khera, MD, Mayo Clinic;
Lisa Ostrosky Sproat, MD, MSW, Mayo Clinic Arizona;
Jeanne Palmer, MD, Mayo Clinic Arizona;
Jeffrey Betcher, BSPharm, Mayo Clinic Arizona;
James L. Slack, MD, Mayo Clinic Arizona
Increased CD68+ Macrophages Are Associated with Liver Fibrosis in a Humanized Chronic Graft-Versus-Host Disease Mouse Model
Hisaki Fujii, MD, PhD, The Hospital for Sick Children;
Zhijuan Luo, MD, PhD, The Hospital for Sick Children;
Hye Jin Kim, MSc, The Hospital for Sick Children;
Susan Newbigging, MSc, DVM, DVSc, Toronto Centre for Phenogenomics;
Armand Keating, MD, Princess Margaret Hospital, University of Toronto;
R. Maarten Egeler, MD, PhD, The Hospital for Sick Children;
Muhammad Ali, MD, The Hospital for Sick Children
Haploidentical Stem Cell Transplantation (HAPLO-HSCT) with Post-Transplant Cyclophosphamide (PT-CY) As Gvhd Prophylaxis in High Risk Hematologic Malignancies: Bone Marrow or Peripheral Blood Progenitors Render Same Results
Jorge Gayoso, HGU Gregorio Marañón;
Pascual Balsalobre, HGU Gregorio Marañón;
Mi Kwon, HGU Gregorio Marañón;
Cristina Castilla-Llorente, Hospital Morales Messeguer;
Maria Jesús Pascual, Hospital Carlos Haya;
Lucía López-Corral, Hospital Clínico;
José Luis Piñana, Hospital Clínico;
Arancha Bermúdez, Hospital Marqués de Valdecilla;
José Antonio Pérez-Simón, Hospital Virgen del Rocío;
Pilar Herrera, Hospital Ramón y Cajal;
Pau Montesinos, Hospital U. La Fe;
Christelle Ferrá, ICO Badalona;
Antonia Sampol, Hospital Son Espasses;
Javier Anguita, HGU Gregorio Marañón;
Inmaculada Heras, Hospital Morales Messeguer;
Diana Champ, HGU Gregorio Marañón;
Carolina Martínez-Laperche, HGU Gregorio Marañón;
Carlos Solano, Hospital Clínico;
Dolores Caballero, Hospital Clínico;
José Luis Diez-Martin, HGU Gregorio Marañón
Increased Incidence of Mixed Chimerism with the Use of Fludarabine – Treosulfan Based Conditioning in Patients Undergoing Allogeneic Stem Cell Transplantation for Thalassaemia Major
Biju George, MD, Christian Medical College;
Auro Viswabandya, MD, Christian Medical College;
Aby Abraham, MD, Christian Medical College;
Eunice Sindhuvi, PhD, Christian Medical College;
Abhijeet Ganapule, MD, Christian Medical College;
Fouzia N A, MD, Christian Medical College;
Anu Korula, MD, Christian Medical College;
Alok Srivastava, MD, Christian Medical College;
Vikram Mathews, MD, Christian Medical College
Enlarged Spleen Prior to Allogeneic Transplantation for Myelofibrosis Is Associated with Poor Engraftment and Increased Non-Relapse Mortality
Usama Gergis, MD, Weill Cornell Medical College;
Koen van Besien, MD, Weill Cornell Medical College;
Tsiporah B. Shore, MD, FRCPC, FACP, Cornell Medical Center Hematology/Oncology, The New York Hospital;
Sebastian Mayer, MD, Weill Cornell Medical Center;
Eric Feldman, MD, Weill Cornell Medical Center;
Gail Roboz, MD, Weill Cornell Medical College;
Ellen Ritchie, MD, Weill Cornell Medical College;
Richard Silver, MD, Weill Cornell Medical college;
Hanhan Wang, Weill Cornell Medical College;
Xi Kathy Zhou, PhD, Weill Cornell Medical College;
Emil Kuriakose, MD, Weill Cornell Medical College
Pilot Clinical Trial of Lymphocyte-Selective Pentostatin Plus Cyclophosphamide Conditioning, High Dose Sirolimus and Pre-Emptive DLI with Rapamycin-Resistant Donor CD4+ T Cells
David Halverson, MD, NCI;
Miriam Mossoba, PhD, NCI;
Brenna Hansen, RN, NCI;
Bazetta Blacklock Schuver, RN, NCI;
Seth M. Steinberg, PhD, National Cancer Institute, National Institutes of Health;
Fran Hakim, PhD, National Cancer Institute, National Institutes of Health;
Syed Abbas Ali, MD, *;
Roger Kurlander, MD, NIH;
Juan Gea-Banacloche, MD, NCI;
Dennis Hickstein, MD, NCI;
Steven Z. Pavletic, MD, National Cancer Institute, National Institutes of Health;
Hanh Khuu, MD, NIH;
David F. Stroncek, MD, National Institutes of Health;
Michael R. Bishop, MD, University of Chicago;
Ronald Gress, MD, * Co-Senior Experimental Transplantation and Immunology Branch/NCI/NIH;
Daniel Fowler, MD, National Cancer Institute, National Institutes of Health
The Safety of Granulocyte Colony Stimulating Factor (G-CSF) Administration in Pediatric Donors before Peripheral Hematopoietic Stem Cell Donation
Amir Ali Hamidieh, M.D., Tehran University of Medical Sciences;
Maryam Behfar, M.D., Tehran University of Medical Sciences;
Sara Faghihi-Kashani, M.D., M.P.H., Tehran University of Medical Sciences;
Ashraf sadat Hosseini, Tehran University of Medical Sciences;
Ardeshir Ghavamzadeh, M.D., Tehran University of Medical Sciences
Donor Cell Cardiac Myeloid Sarcoma Following Umbilical Cord Transplantation
Christi Ann Hayes, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Luis Isola, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Eileen Scigliano, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Keren Osman, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Amir Steinberg, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Alla Keyzner, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Anne S. Renteria, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Bruce Petersen, MD, Mount Sinai Medical Center;
Adriana K. Malone, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai
ABO Blood Group Incompatibility Has No Impact on the Outcomes in Patients with Myeloid Neoplasms That Underwent Reduced Intensity Allogenic Hematopoietic Stem Cell Transplantation – a Single Institution Series of 148 Patients
Mehrdad Hefazi, MD, Mayo Clinic;
Mark R. Litzow, MD, Mayo Clinic Rochester;
William Hogan, MBBCh, Mayo Clinic;
Dennis A. Gastineau, MD, Mayo Clinic;
Eapen K Jacob, M.D., Mayo Clinic;
Shahrukh Hashmi, MD, MPH, Mayo Clinic Rochester;
Aref Al-kali, MD, Mayo Clinic;
Mrinal Patnaik, MBBS, Mayo Clinic
Early Hematopoietic Cell Transplant (HCT) Outcomes of Children with Severe Combined Immunodeficiency Disease (SCID): The First Seventy Four Patients of the Primary Immune Deficiency Treatment Consortium (PIDTC) Prospective Study 6901
Jennifer Heimall, MD, The Children's Hospital of Philadelphia;
Brent R. Logan, PhD, Medical College of Wisconsin;
Morton J Cowan, MD, UCSF Benioff Children's Hospital;
Luigi D. Notarangelo, MD, Children’s Hospital Boston, Harvard Medical School;
Linda M Griffith, MD, PhD, DAIT, NIAID, NIH;
Jennifer Puck, MD, UCSF Benioff Children's Hospital;
Suhag Parikh, MD, Duke University Medical Center;
Richard J O'Reilly, MD, Memorial Sloan Kettering Cancer Center;
Sung-Yun Pai, MD, Boston Children's Hospital;
Imelda C Hanson, MD, Baylor College of Medicine, Texas Children's Hospital;
Caridad Martinez, MD, Baylor College of Medicine, Texas Children's Hospital;
Michael A. Pulsipher, MD, University of Utah School of Medicine;
Neena Kapoor, MD, Children's Hospital Los Angeles;
Frederick Goldman, MD, The University of Alabama at Birmingham;
Morris Kletzel, MD, FAAP, MBA, Northwestern University Feinberg School of Medicine;
Lisa Filipovich, MD, Cincinnati Children's Hospital Medical Center;
Geoff Cuvellier, MD, CC Manitoba;
Monica Thakar, MD, Medical College of Wisconsin;
Lauri Burroughs, MD, Fred Hutchinson Cancer Research Center;
Alan Knudsen, MD, St Louis University;
James A Connelly, MD, University of Michigan;
Troy C Quigg, DO, MS, Texas Transplant Institute;
Angela R. Smith, MD, MS, University of Minnesota Medical Center, Fairview;
Kathleen Sullivan, MD, PhD, The Children's Hospital of Philadelphia;
Brett J. Loechelt, MD, Children's National Medical Center;
Alfred P. Gillio, MD, Hackensack University Medical Center;
Elie Haddad, MD PhD, Ste-Justine Hospital;
Donald B. Kohn, MD, Mattel Children's Hospital, University of California, Los Angeles;
Thomas Fleisher, MD, National Institutes of Health;
William Shearer, MD, PhD, Baylor College of Medicine, Texas Children's Hospital;
Christopher C. Dvorak, MD, University of San Francisco;
Rebecca H Buckley, MD, Duke University Medical Center
Long-Term Follow-up and Experience with Donor Lymphocyte Infusion (DLI); Is It Time for a Paradigm Shift?
Nasheed Mohammad Hossain, MD, Fox Chase Cancer Center/Temple University Hospital;
Thomas Klumpp, MD, Thomas Jefferson University Hospital;
John Ulicny, MS, Temple University Hospital;
Michael Garner, Temple University Hospital;
Patricia Lamont Kropf, MD, Temple University;
Kenneth F. Mangan, MD, Temple University BMT Program;
Stefan Klaus Barta, MD, MRCP, MS, Fox Chase Cancer Center;
Henry C Fung, MD, Temple University Hospital/Fox Chase Cancer Center;
Mary Ellen Martin, MD, Temple University
Registry Efforts to Improve Success of Unrelated Donor Searching for African American Patients
Katie A. Howe, Ph.D., National Marrow Donor Program;
Kevin Tram, B.A., National Marrow Donor Program;
Beth Beduhn, B.S., National Marrow Donor Program;
Rachel Fonstad, M.S., Center for International Blood and Marrow Transplant Research, National Marrow Donor Program;
Deidre M. Kiefer, M.P.H., Center for International Blood and Marrow Transplant Research, National Marrow Donor Program;
Jason Dehn, M.P.H., National Marrow Donor Program
Graft Versus Host Disease Prophylaxis with a Bortezomib-Based Regimen without G-CSF Support for Patients Undergoing MUD Transplant: Evaluation of Engraftment Kinetics and Transplant Outcomes
Antonio M Jimenez, MD, Rush University Medical Center;
Alfonso D Moreno, Rush University Medical Center;
John Maciejewski, MD, PhD, Rush University Medical Center;
Andrew Dalovisio, MD, Rush University Medical Center;
Deborah Katz, MD, Rush University Medical Center;
Christina Havey, Rush University Medical Center;
Nazneen Merchant, MBBS, Rush University Medical Center;
Henry C Fung, MD, Temple University Hospital/Fox Chase Cancer Center;
Sunita Nathan, MD, Rush University Medical Center
Long-Term Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation with Intensified Myeloablative Conditioning for Refractory Hematologic Malignancies
Naomi Kawashima, MD, Japanese Red Cross Nagoya First Hospital;
Takahiko Sato, Japanese Red Cross Nagoya First Hospital;
Miho Kato, Japanese Red Cross Nagoya First Hospital;
Marie Nakashima, Japanese Red Cross Nagoya First Hospital;
Yusuke Kagaya, Japanese Red Cross Nagoya First Hospital;
Kyoko Watakabe, Japanese Red Cross Nagoya First Hospital;
Aika Seto, Japanese Red Cross Nagoya First Hospital;
Nobuaki Fukushima, Japanese Red Cross Nagoya First Hospital;
Shingo Kurahashi, Japanese Red Cross Nagoya First Hospital;
Yukiyasu Ozawa, Japanese Red Cross Nagoya First Hospital;
Koichi Miyamura, Japanese Red Cross Nagoya First Hospital
Transplant Outcomes in Older Patients Are Comparable to Outcomes in Younger Patients after Hopkins' Non-Myeloablative Flu Cy TBI + PT-Cy Regimen
Jesse Keller, MD, Washington University in St Louis;
John F. DiPersio, MD, PhD, Washington University School of Medicine;
Geoffrey L. Uy, MD, Washington University School of Medicine;
Peter Westervelt, MD, PhD, Washington University School of Medicine;
Camille Abboud, MD, Washington University School of Medicine;
Pavan Kumar Bhamidipati, Washington University School of Medicine;
Ravi Vij, MD, Washington University School of Medicine;
Amanda Cashen, MD, Washington University School of Medicine;
Kathryn Trinkaus, Ph.D., Washington University School of Medicine;
Rizwan Romee, MD, Washington University School of Medicine
Secondary Graft Failure in Allogeneic Stem Cell Transplantation for Myelofibrosis - a Single Institution Experience
Alla Keyzner, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Yan A Zhao, Mount Sinai Icahn School Of Medicine;
Anne S. Renteria, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Adriana K. Malone, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Keren Osman, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Eileen Scigliano, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Amir Steinberg, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Luis Isola, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai
Allogeneic Stem Cell Transplant Improves the Outcome of Patients with Acute Erythroleukemia: Single Center Analysis
Saranya Kodali, MD, University of Massachusetts;
Eswar Tipirneni, MD, University of Massachusetts;
Hongbo Yu, MD, PhD, University of Massachusetts;
Zheng Zhou, MD, PhD, University of Massachusetts;
Muthalagu Ramanathan, MD, University of Massachusetts;
Rajneesh Nath, MD, University of Massachusetts;
Jan Cerny, MD, PhD, FACP, University of Massachusetts
The Blood Concentration of Tacrolimus Is Affected By Pir Following Cord Blood Transplantation
Taro Kurihara Jr., M.D, Nagano Red Cross Hospital;
Toshimitsu Ueki, M.D, PhD, Nagano Red Cross Hospital;
HIroko Kaiume, M.D, Nagano Red Cross Hospital;
Wataru Takeda, M.D, Nagano Red Cross Hospital;
Takehiko Kirihara, M.D, Nagano Red Cross Hospital;
Keijiro Sato, M.D, Nagano Red Cross Hospital;
Yuki Hiroshima, M.D, PhD, Nagano Red Cross Hospital;
Masahiko Sumi, M.D, PhD, Nagano Red Cross Hospital;
Mayumi Ueno, M.D, Nagano Red Cross Hospital;
Naoaki Ichikawa, M.D, PhD, Nagano Red Cross Hospital;
Hikaru Kobayashi, M.D, PhD, Nagano Red Cross Hospital
Economic Consequences of Cytomegalovirus Disease Among Stem Cell Transplant Recipients
Alexander R. Macalalad, MD, MS, Analysis Group, Inc.;
Hongbo Yang, PhD, Analysis Group, Inc.;
Zhou Zhou, MS, Analysis Group, Inc.;
Eric Q. Wu, PhD, Analysis Group, Inc.;
Paresh Chaudhari, PharmD, MPH, Astellas Scientific and Medical Affairs, Inc.;
Edward Lee, PharmD, Astellas Scientific and Medical Affairs, Inc.;
David R. Snydman, MD, Tufts Medical Center
Salvage Therapy for Graft Rejection with Second Haploidentical Allogeneic Stem Cell Transplantion (Haplo-HCT) from a Second Related Donor
Vikas Bhushan, MD, Texas Oncology, PA;
John Mathews, MD, Texas Oncology, PA;
Estil Vance, MD, Baylor University Medical Center;
Carolina Escobar, MD, Medical City Hospital;
Jennifer Kurre, Medical City Dallas Hospital;
Jennifer Potter, Texas Oncology, PA;
Katherine Sellers, Texas Oncology, PA;
Maria Custodio, BSMT, Medical City Dallas Hospital;
Afzal Nikaein, PhD, Texas Medical Specialty
The Incidence of Venous Thromboembolism (VTE) in 892 Allogeneic Hematopoietic Cell Transplant (allo-HCT) Recipients ( A single institution study comparison of VTE incidence with sirolimus versus non-sirolimus-based GVHD prophylaxis)
John Mathews, MD, Texas Oncology, PA;
Binglin Yue, MS, H. Lee Moffitt Cancer Center and Research Institute;
Josephine Emole, MD, H. Lee Moffitt Cancer Center and Research Institute;
Taiga Nishihori, MD, H. Lee Moffitt Cancer Center and Research Institute;
Vikas Bhushan, MD, Texas Oncology, PA;
Michael L. Nieder, MD, H. Lee Moffitt Cancer Center and Research Institute;
Frederick L Locke, MD, H. Lee Moffitt Cancer Center and Research Institute;
Jongphil Kim, PhD, H. Lee Moffitt Cancer Center and Research Institute;
Claudio Anasetti, MD, H. Lee Moffitt Cancer Center and Research Institute;
Hugo Fernandez, MD, H. Lee Moffitt Cancer Center and Research Institute
Pre-Transplant Consolidation and Cost Effectiveness of RIC Allogeneic SCT in Patients of AML-CR1 in India
Abhijeet Ganapule, MD, Christian Medical College;
Shashikant Apte, MD, Sahayadhri Hospital;
Navin Khattry, MD, ACTREC, Tata Memorial Center;
Reetu Jain, MD, Jaslok Hospital and Research Center;
Joseph M John, MD, Christian Medical College;
Sharat Damodar, MD, Mazumdar Shaw Cancer Center;
Lalit Kumar, Institute Rotary Cancer Hospital, AIIMS;
Dinesh Bhurani, DM, Rajiv Gandhi Cancer and Research Center;
Kavitha Lakshmi, MSc, Christian Medical College;
Rayaz Ahmed, MD, Rajiv Gandhi Cancer and Research Center;
Ranjit Kumar Sahoo, Institute Rotary Cancer Hospital, AIIMS;
Nataraj K Srinivasarao, MD, Mazumdar Shaw Cancer Center;
Amrith Mathew, MD, Christian Medical College;
Tapan Saikia, Jaslok Hospital and Research Center;
Alok Gupta, MD, ACTREC, Tata Memorial Center;
Sachin Punatar, MD, ACTREC, Tata Memorial Center;
Kannan Subramani, MD, Sahayadhri Hospital;
Aby Abraham, MD, Christian Medical College;
Auro Viswabandya, MD, Christian Medical College;
Alok Srivastava, MD, Christian Medical College;
Biju George, MD, Christian Medical College;
Vikram Mathews, MD, Christian Medical College
Allogeneic Hematopoietic Cell Transplantation Is a Curative Treatment Option for Advanced-Stage Chronic Myeloid Leukemia in the TKI Era, a Single Institution Retrospective Study of 29 Post AP/BC Cases
Hiroki Mizumaki, MD, Toranomon Hospital;
Shinsuke Takagi, MD, PhD, Toranomon Hospital;
Naoyuki Uchida, MD, PhD, Toranomon Hospital;
Kosei Kageyama, MD, Toranomon Hospital;
Daisuke Kaji, MD, Toranomon Hospital;
Sachie Wada, MD, Toranomon Hospital;
Aya Nishida, MD, Toranomon Hospital;
Kazuya Ishiwata, MD, Toranomon Hospital;
Masanori Tsuji, MD, Toranomon Hospital;
Hisashi Yamamoto, MD, Toranomon Hospital;
Go Yamamoto, MD, PhD, Toranomon Hospital;
Yuki Asano-Mori, MD, PhD, Toranomon Hospital;
Shigeyoshi Makino, MD, PhD, Toranomon Hospital;
Akiko Yoneyama, MD, PhD, Toranomon Hospital;
Atsushi Wake, MD, PhD, Toranomon Hospital;
Koji Izutsu, MD, PhD, Toranomon Hospital;
Shuichi Taniguchi, MD, PhD, Toranomon Hospital
Clinical Outcomes of HLA-DPB1 Mismatches in 10/10 HLA-Matched Donor-Recipient Pairs Undergoing Allogeneic Stem Cell Transplant
Ann M. Moyer, MD, PhD, Mayo Clinic;
Shahrukh Hashmi, MD, MPH, Mayo Clinic Rochester;
Cynthia M. Kroning, Mayo Clinic;
Walter K. Kremers, PhD, Mayo Clinic;
Steven R. De Goey, Mayo Clinic;
Mrinal Patnaik, MBBS, Mayo Clinic;
Mark R. Litzow, MD, Mayo Clinic Rochester;
Dennis A. Gastineau, MD, Mayo Clinic;
William Hogan, MBBCh, Mayo Clinic;
Justin D. Kreuter, MD, Mayo Clinic;
Laurie L. Voit, Mayo Clinic;
Manish Gandhi, MD, Mayo Clinic
Feasibility of Day 4 G-CSF Mobilized Peripheral Blood Stem Collection from HLA-Matched Sibling Donors
Laura F Newell, MD, Oregon Health & Science University;
Rebekah J Knight, Oregon Health and Science University;
Kelsea M Shoop, Oregon Health & Science University;
Sara N Murray, HCP Cryo Lab, Oregon Health and Science University;
Susan Slater, FNP, Oregon Health & Science University;
Richard T. Maziarz, MD, Oregon Health and Science University;
Gabrielle Meyers, MD, Oregon Health & Science University
Placental Growth Factor (PlGF) in Allogeneic Hematopoietic Cell Transplantation (HCT): Clinical, Immunologic, and Pathologic Correlates
Laura F Newell, MD, Oregon Health & Science University;
Erin R Kavanagh, Oregon Health & Science University;
Jessica T Leonard, MD, Oregon Health & Science University;
Guang Fan, MD, PhD, Oregon Health & Science University;
Gabrielle Meyers, MD, Oregon Health & Science University;
Shernan Holtan, MD, University of Minnesota
Viral Infections after Umbilical Cord Blood Transplant: A Retrospective Analisys of 156 Children Transplanted at a Single Institution
Samantha Nichele, MD, Federal University of Paraná;
Lisandro Ribeiro, MD, Federal University of Paraná;
Gisele Loth, MD, Federal University of Paraná;
Fernanda Fetter Scherer, MD, Federal University of Paraná;
Adriana Koliski, MD, Federal University of Parana;
Rebeca Toassa Mousquer, MD, Federal University of Parana;
Cilmara Kuwahara, MD, Hospital Infantil Pequeno Príncipe;
Ana Luiza Rodrigues de Melo, MD, Hospital Infantil Pequeno Príncipe;
Tairine Lippi Gautério, MD, Federal University of Paraná;
Flávia da Nóbrega Jannini, MD, Federal University of Paraná;
Natália Dettoni Longo, MD, Federal University of Paraná;
Ricardo Petterle, Federal University of Paraná;
Carmem Bonfim, MD, Federal University of Paraná
Paradoxical Effect of Donor Cytomegalovirus (CMV) Status on CMV Reactivation after T-Cell Depleted (TCD) Stem Cell Transplantation (SCT)
Yao-Ting Huang, PhD, MPH, Memorial Sloan Kettering Cancer Center;
Julia Foldi, PhD, Memorial Sloan Kettering Cancer Center;
Kun Xiao, MD MPH, Memorial Sloan Kettering Cancer Center;
Dick Chung, Memorial Sloan Kettering Cancer Center;
Dionysios Neofytos, MD, Memorial Sloan Kettering Cancer Center;
Yovanna Kolitsopoulos, BS, Memorial Sloan Kettering Cancer Center;
Molly Maloy, MS, Memorial Sloan Kettering Cancer Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Esperanza Papadopoulos, MD, Memorial Sloan Kettering Cancer Center;
Ann A. Jakubowski, PhD, MD, Memorial Sloan Kettering Cancer Center;
Genovefa Papanicolaou, MD, Memorial Sloan Kettering Cancer Center
Cluster of Fulminant Toxoplasmosis in T-Cell Depleted (TCD) and Cord Blood (CB) Stem Cell Transplant (SCT) Recipients: Impact of Aggressive Prophylaxis and Routine Monitoring By Toxoplasma PCR for High Risk Patients
Yao-Ting Huang, PhD, MPH, Memorial Sloan Kettering Cancer Center;
Ann A. Jakubowski, PhD, MD, Memorial Sloan Kettering Cancer Center;
Hugo Castro-Malaspina, M.D., Memorial Sloan Kettering Cancer Center;
Juliet Barker, MBBS (Hons) FRACP, Memorial Sloan Kettering Cancer Center;
Guenther Koehne, PhD, MD, Memorial Sloan Kettering Cancer Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Genovefa Papanicolaou, MD, Memorial Sloan Kettering Cancer Center
The Relationship Between Pre-Transplant 25-Hydroxy-Vitamin D Levels, Survival and Graft-Versus-Host Disease, in Allogeneic Haematopoietic Stem Cell Transplantation
Travis Perera, MBChB, FRACP, FRCPA, Royal Melbourne Hospital;
Andrew Boon Ming Lim, MBBS, FRACP, FRCPA, University of Melbourne;
Kate Mason, Royal Melbourne Hospital;
Jeffrey Szer, MB, BS, FRACP, Royal Melbourne Hospital;
David Stuart Ritchie, MBChB FRACP FRCPA PhD, Peter MacCallum Cancer Centre
Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML
Uday R. Popat, MD, UT MD Anderson Cancer Center;
Rima Saliba, PhD, The University of Texas MD Anderson Cancer Center;
Betul Oran, MD, The University of Texas MD Anderson Cancer Center;
Julianne Chen, BS, The University of Texas MD Anderson Cancer Center;
Amin Alousi, MD, UT MD Anderson Cancer Center;
Sairah Ahmed, The University of Texas MD Anderson Cancer Center;
Qaiser Bashir, MD, The University of Texas MD Anderson Cancer Center;
Stefan O. Ciurea, MD, The University of Texas MD Anderson Cancer Center;
Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center;
Roy B. Jones, MD, PhD, The University of Texas MD Anderson Cancer Center;
Partow Kebriaei, MD, The University of Texas MD Anderson Cancer Center;
Issa F. Khouri, MD, The University of Texas MD Anderson Cancer Center;
Yago L. Nieto, MD, PhD, UT MD Anderson Cancer Center;
Amanda Olson, M.D., The University of Texas MD Anderson Cancer Center;
Simrit Parmar, MD, The University of Texas MD Anderson Cancer Center;
Nina Shah, MD, The University of Texas MD Anderson Cancer Center;
Elizabeth J. Shpall, MD, UT MD Anderson Cancer Center;
Muzaffar H. Qazilbash, MD, The University of Texas MD Anderson Cancer Center;
Borje S. Andersson, MD, PhD, The University of Texas MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center
Unmanipulated Bone Marrow As Third Party Donor for Unrelated Cord Blood Transplant Decreases 100-Day Mortality in Children
Oscar Ramirez, MD MPhil, Centro Médico Imbanaco;
Margarita Quintero, MD MSc, Centro Médico Imbanaco;
Carlos Andres Portilla, MD, Hospital Universitario;
Eduardo Lopez, MD, Hospital Universitario del Valle;
Viviana Lotero, MD, Fundación Valle del Lili;
Juan Manuel Herrera, MD, Centro Médico Imbanco
Characteristics and Preliminary Clinical Results of a Cohort of Patients in Santiago, Chile, Undergoing Haploidentical Hematopoietic Cell Transplantation with Postransplant Cyclophosphamide
Javier Diaz, MD, Pontifical Catholic University;
Veronica Jara, RN, Pontifical Catholic University;
Pablo Bertin, MD, Pontifical Catholic University;
Francisca Negrete, RN, Clinica Santa Maria;
Claudio Mosso, MD, Clinica Santa Maria;
Cristian Carvallo, MD, Clinica Santa Maria;
Pablo A Ramirez, MD, Pontifical Catholic University
Eliminating Cross Contamination from Intravenous Cyclosporine and Tacrolimus and Accurate Blood Sampling
Nicole Ritzau, RN, BSN, BMTCN, National Institutes of Health, Clinical Center;
CAPT Diane Aker, RN, BSN, MBA, National Institutes of Health, Clinical Center
Reduced-Intensity Stem Cell Allografting for PNH Patients in the Eculizumab Era: The Mexican Experience
Alejandro Schcolnik-Cabrera, MD, Universidad Nacional Autonoma de Mexico;
Nancy Labastida-Mercado, MD, Clinica Ruiz de Puebla;
Samantha L Galindo-Becerra, MD, Clinica Ruiz de Puebla;
David Gomez-Almaguer, MD, University Hospital of Monterrey;
Miguel A Herrera-Rojas, MD, University Hospital of Monterrey;
Guillermo J Ruiz-Delgado, MD, Laboratorios Clinicos de Puebla, Clinica Ruiz;
Guillermo J Ruiz-Arguelles, MD, Clinica Ruiz
Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation
Christine E. Ryan, Stanford University School of Medicine;
Aaron C. Logan, University of California San Francisco;
Andrew Rezvani, Stanford University School of Medicine;
Manali Kamdar, Stanford University School of Medicine;
Hideki Nakasone, Stanford University School of Medicine;
Bita Sahaf, Stanford University School of Medicine;
Joanne Otani, Stanford University School of Medicine;
Kiara Cerda, Stanford University School of Medicine;
Katherine A. Kong, Sequenta, Inc.;
Mark Klinger, Sequenta, Inc.;
Malek Faham, Sequenta, Inc.;
Steven Coutre, Stanford University School of Medicine;
David B. Miklos, Stanford University School of Medicine
High Disease-Free Survival (DFS) Supports Continued Investigation of Double-Unit Cord Blood Transplantation (DCBT) in Children with High-Risk Acute Leukemia Especially in the Setting of Single Units with Low Dose and/or a High Degree of HLA-Mismatch
Andromachi Scaradavou, MD, New York Blood Center;
Marissa Lubin, BA, Memorial Sloan Kettering Cancer Center;
Patrick Hilden, PhD, Memorial Sloan Kettering Cancer Center;
Farid Boulad, MD, Memorial Sloan Kettering Cancer Center;
Kevin J. Curran, MD, Memorial Sloan Kettering Cancer Center;
Rachel Kobos, MD, Memorial Sloan Kettering Cancer Center;
Susan E. Prockop, MD, Memorial Sloan Kettering Cancer Center;
Richard J. O'Reilly, MD, Memorial Sloan Kettering Cancer Center;
Jo-ann Tonon, BS, Memorial Sloan Kettering Cancer Center;
Courtney Byam, BS, Memorial Sloan Kettering Cancer Center;
Peter G Steinherz, MD, Memorial Sloan Kettering Cancer Center;
Neerav Shukla, MD, Memorial Sloan Kettering Cancer Center;
Aisha Nasreen Hasan, MD, Memorial Sloan Kettering Cancer Center;
Thomas M Renaud, M.D., Memorial Sloan Kettering Cancer Center;
Nicole Zakak, PNP, Memorial Sloan Kettering Cancer Center;
Nancy A Kernan, MD, Memorial Sloan Kettering Cancer Center;
Juliet Barker, MBBS (Hons) FRACP, Memorial Sloan Kettering Cancer Center
Ex Vivo T Cell Depleted HLA-Matched PBSCT with Post-Transplant Activated Donor-Derived NK Cell Infusions for High-Risk Acute Lymphoblastic Leukemia
Nirali N Shah, MD, MHSc, National Cancer Institute/National Institutes of Health;
Bonnie Yates, BSN, National Cancer Institute/National Institutes of Health;
Cindy Delbrook, BSN, National Cancer Institute/National Institutes of Health;
Daniel W Lee, MD, National Cancer Institute/National Institutes of Health;
Thomas Fleisher, MD, National Cancer Institute/National Institutes of Health;
Shakuntala Rampertaap, National Cancer Institute/National Institutes of Health;
Kimberly Lemberg, National Cancer Institute/National Institutes of Health;
Marianna Sabatino, MD, PhD, National Institutes of Health;
David F. Stroncek, MD, National Institutes of Health;
Hua Zhang, PhD, National Cancer Institute/National Institutes of Health;
Terry J Fry, MD, National Cancer Institute/National Institutes of Health;
Crystal L Mackall, MD, National Cancer Institute/National Institutes of Health
Differential Impact of Dose Escalated Busulfan on Allogeneic Transplant for High, Intermediate and Low Risk Disease
Thomas C. Shea, MD, University of North Carolina at Chapel Hill;
Christine M. Walko, PharmD, BCOP, Moffitt Cancer Center;
Yunro Chung, UNC School of Public Health;
Anastasia Ivanova, PhD, University of North Carolina at Chapel Hill;
Kamakshi V. Rao, PharmD, University of North Carolina Hospitals and Clinics;
James Coghill, MD, Univ of North Carolina;
Stefanie Sarantopoulos, MD, PhD, Duke University;
William A. Wood, MD, MPH, University of North Carolina - Chapel Hill;
Paul Armistead, MD, PhD, Univeristy of North Carolina;
Don A Gabriel, MD, PhD, Univ of NC School of Medicine;
Jonathan S. Serody, MD, University of North Carolina
Predictive Limitations of Hematopoietic Stem Cell Transplantation Associated Mortality: A Machine Learning in-Silico Analysis of the EBMT - Acute Leukemia Working Party Registry
Roni Shouval, MD, The Chaim Sheba Medical Center, Tel-Hashomer, Division of Hematology and Bone Marrow Transplantation;
Myriam Labopin, MD, EBMT Paris study office / CEREST-TC;
Ron Unger, PhD, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University;
Sebastian Giebel, MD, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch;
Fabio Ciceri, MD, San Raffaele Scientific Institute;
Christoph Schmid, MD, Department of Hematology and Oncology, Klinikum Augsburg, Ludwig-Maximilians-University;
Jordi Esteeve, MD, Hematology Department, IDIBAPS, Hospital Clínic;
Norbert Gorin, MD, Hopital Saint-Antoine;
Frédéric Baron, MD, PhD, University of Liège, GIGA-I3;
Bipin N. Savani, MD, Vanderbilt University;
Mohamad Mohty, MD, PhD, Department of Haematology, Saint Antoine Hospital;
Arnon Nagler, MD, The Chaim Sheba Medical Center, Tel-Hashomer, Division of Hematology and Bone Marrow Transplantation
Outcomes of Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Jane Olsen, NP, Mayo Clinic Arizona;
Qing Wu, Mayo Clinic Arizona;
Nandita Khera, MD, Mayo Clinic Arizona;
Roberta Adams, MD, Mayo Clinic Arizona;
Veena Fauble, MD, Mayo Clinic Arizona;
Jose Leis, MD, PhD, Mayo Clinic Arizona;
Pierre Noel, MD, Mayo Clinic Arizona;
Jeanne Palmer, MD, Mayo Clinic Arizona;
James L. Slack, MD, Mayo Clinic Arizona;
Lisa Ostrosky Sproat, MD, MSW, Mayo Clinic Arizona
Bendamustine-Brentuximab: Bridging to Transplant
Amir Steinberg, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Anne S. Renteria, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Eileen Scigliano, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Christi Hayes,, MD, Mount Sinai Hospital;
Maureen Kane, NP, Mount Sinai Medical Center;
Keren Osman, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Adriana Malone, MD, Mount Sinai School of Medicine;
Alla Keyzner, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai;
Luis Isola, MD, Bone Marrow and Stem Cell Transplantation, Icahn School of Medicine at Mount Sinai
Prospective Multicenter Phase II Study of HLA-Haploidentical Peripheral Blood Stem Cell Transplantation after Reduced-Intensity Conditioning with Post-Transplant Cyclophosphamide: First Analysis of the JSCT Haplo13 Study
Junichi Sugita, MD, Hokkaido University Graduate School of Medicine;
Naomi Kawashima, MD, Japanese Red Cross Nagoya First Hospital;
Tomoaki Fujisaki, MD, Matsuyama Red Cross Hospital;
Kazuhiko Kakihana, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital;
Naoyuki Uchida, MD, PhD, Toranomon Hospital;
Yoshinobu Maeda, MD, Okayama University Graduate School of Medicine;
Shuichi Ota, MD, Department of Hematology;
Keitaro Matsuo, MD, Kyushu University Faculty of Medical Sciences;
Toshihiro Miyamoto, MD, Kyushu University Graduate School of Medical Science;
Koji Nagafuji, MD, PhD, Kurume University School of Medicine;
Tetsuya Eto, MD, PhD, Hamanomachi Hospital;
Koichi Akashi, MD, PhD, Kyushu University Graduate School of Medical Science;
Shuichi Taniguchi, MD, Toranomon Hospital;
Mine Harada, MD, Karatsu Higashimatsuura Medical Association;
Takanori Teshima, MD, PhD, Hokkaido University Graduate School of Medicine
Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation
Anthony D. Sung, MD, Duke University Medical Center;
Diana Cardona, MD, Duke University Medical Center;
Krista Rowe, RN, MSN, AOCNS, Duke University Medical Center;
Hossein Mehdikhani, Duke University Medical Center;
Claire Detweiler, MD, Duke University Medical Center;
Michael Shealy, MD, Duke University Medical Center;
Daniel Wild, MD, Duke University Medical Center;
Martin Poleski, MD, Duke University Medical Center;
Constance Cirrincione, MS, Duke University Medical Center;
Zhiguo Li, PhD, Duke University Medical Center;
Nelson J. Chao, MD, MBA, Duke University Medical Center;
Keith Sullivan, MD, Duke University Medical Center
Outcomes of Bone Marrow or Cord Blood Matched Related Transplantation for Children with Sickle Cell Disease: Experience of a Canadian Center
Pierre Teira, MD, MSc, CHU Sainte Justine;
Henrique Bittencourt, MD, CHU Sainte Justine;
Yves Pastore, MD, CHU Sainte Justine;
Nancy Robitaille, MD, CHU Sainte Justine;
Michel Duval, CHU Sainte-Justine
Experience with Administration of Ruxolitinib after Allogeneic Stem Cell Transplantation (alloSCT) in Patients with Myelofibrosis
Eswar Tipirneni, MD, University of Massachusetts;
Saranya Kodali, MD, University of Massachusetts;
Muthalagu Ramanathan, MD, University of Massachusetts;
Rajneesh Nath, MD, University of Massachusetts;
Jan Cerny, MD, PhD, FACP, University of Massachusetts
Delayed and Sudden Lymphocyte Recovery Is the Predictive Sign of Primary Graft Failure Following CBT, Single Institute Analysis of 105 CBT
Toshimitsu Ueki, M.D, PhD, Nagano Red Cross Hospital;
HIroko Kaiume, M.D, Nagano Red Cross Hospital;
Takehiko Kirihara, M.D, Nagano Red Cross Hospital;
Wataru Takeda, M.D, Nagano Red Cross Hospital;
Taro Kurihara Jr., M.D, Nagano Red Cross Hospital;
Keijiro Sato, M.D, Nagano Red Cross Hospital;
Ikuo Shimizu, MD, Nagano Red Cross Hospital;
Yuki Hiroshima, M.D, PhD, Nagano Red Cross Hospital;
Masahiko Sumi, M.D, PhD, Nagano Red Cross Hospital;
Mayumi Ueno, M, D, Nagano Red Cross Hospital;
Naoaki Ichikawa, M.D, PhD, Nagano Red Cross Hospital;
Hikaru Kobayashi, M.D, PhD, Nagano Red Cross Hospital
Viral Load in Hematopoietic Cell Transplant Recipients Infected with Human Rhinovirus Correlates with Burden of Symptoms
Alpana Waghmare, Fred Hutchinson Cancer Research Center;
Jane M Kuypers, PhD, University of Washington;
Hu Xie, MS, Fred Hutchinson Cancer Research Center;
Wendy Leisenring, Fred Hutchinson Cancer Research Center;
Angela P Campbell, Centers for Disease Control;
Keith R Jerome, MD, PhD, University of Washington;
Janet A Englund, MD, University of Washington;
Michael J. Boeckh, MD, Fred Hutchinson Cancer Research Center
Therapeutic Drug Monitoring of Tacrolimus in Allogeneic Hematopoietic Transplant Patients in a Single Oncology Center
Kathleen West, B.S. Pharm D, Roswell Park Cancer Institute;
Philip L. McCarthy, MD, Roswell Park Cancer Institute;
Jordan D Pleskow, Pharm D, Roswell Park Cancer Institute;
Maureen Ross, MD, PhD, Roswell Park Cancer Institute;
Hong Liu, MD, PhD, Roswell Park Cancer Institute;
George L Chen, MD, Roswell Park Cancer Institute;
Michael Cimino, B.S., M.S., Roswell Park Cancer Institute;
Michele L Burgess, PA, Roswell Park Cancer Institute;
Molly B Aungst, NP, Roswell Park Cancer Institute;
Justine E Bertolo, NP, Roswell Park Cancer Institute;
Melissa M Everett, PA, Roswell Park Cancer Institute;
Eric J Breitwieser, PA, Roswell Park Cancer Institute;
Dodie M Killock, RN, Roswell Park Cancer Institute
DNA Methyltransferase-1 (DNMT1): A Flow Cytometric Pharmacodynamic Assay for Azacitidine Hypomethylating Therapy after Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT)
Basem M. William, MD, MRCP(UK), University Hospitals Seidman Cancer Center and Case Western Reserve University;
Philip Woost, PhD, Case Western Reserve University;
Reda Mahfouz, MD, PhD, Cleveland Clinic Foundation;
Lauren Brister, CNP, AOCNP, University Hospitals Seidman Cancer Center;
Paolo Caimi, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Erica Campagnaro, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Brenda Cooper, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Hillard M. Lazarus, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Yogen Saunthararajah, MD, Cleveland Clinic Foundation;
Marcos J. G. de Lima, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Krishna V. Komanduri, MD, University of Miami, Sylvester Comprehensive Cancer Center;
James Jacobberger, PhD, Case Western Reserve University
Novel Imaging Analysis of the Marrow Compartment after Myeloablative HSCT Reveals the Kinetics and Degree of Myeloablation and Cell Recovery
Jennifer Holter Chakrabarty, M.D., University of Oklahoma -Peggy and Charles Stephenson Cancer Center;
Chuong T Nguyen, PhD, * Co-First School of Electrical and Computer Engineering, University of Oklahoma;
Joseph P Havlicek, PhD, School of Electrical and Computer Engineering, University of Oklahoma;
Sara K Vesely, PhD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center;
Liza Lindenberg, MD, Molecular Imaging Branch, NIH;
Steve Adler, PhD, Molecular Imaging Branch, NIH;
Bazetta AJ Blacklock-Schuver, RN, ETIB/NCI/NIH;
Karen Kurdziel, MD, Molecular Imaging Branch, NIH;
Frank Lin, PhD, Cancer Imaging Program, National Cancer Institute, NIH;
Daniele Avila, CRNP, ETIB/NCI/NIH;
George B. Selby, MD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center;
Jennifer Mann, NP, ETIB/NCI/NIH;
Jennifer Hsu, RN, ETIB/NCI/NIH;
Amy Chai, RN, ETIB/NCI/NIH;
Robert B. Epstein, MD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center;
Ngoc Quyen T Duong, PhD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center;
Shibo Li, MD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center;
Teresa Kraus, MD, Stephenson Cancer Center, University of Oklahoma Health Sciences Center;
Sarah Hopps, PharmD, BSPS, BCOP, University of Oklahoma;
Tom Pham, MSI, Stephenson Cancer Center, University of Oklahoma Health Sciences Center;
Catherine M. Bollard, MD, Children's National Medical Center;
Peter Choyke, MD, Molecular Imaging Branch, NIH;
Ronald Gress, MD, * Co-Senior Experimental Transplantation and Immunology Branch/NCI/NIH;
Kirsten M. Williams, MD, CNMC/National Cancer Institute, NIH
In Situ Manipulation of Tregs Via Combined IL-2 and TNFRSF25 Signaling Pre- and Post-Transplant: A Novel Approach to Regulate Gvhd By Marked Expansion of CD4+Foxp3+ T Cells
Dietlinde Wolf, PhD, Miller School of Medicine, University of Miami;
Henry Barreras, Miller School of Medicine, University of Miami;
Krishna V. Komanduri, MD, University of Miami, Sylvester Comprehensive Cancer Center;
Eckhard R Podack, MD, PhD, Miller School of Medicine, University of Miami;
Robert B Levy, PhD, U of Miami Schl of Med Micrbio/Imm
ATG Use and Post-Allogeneic Transplant Viral EBV, CMV, HHV-6 and HHV-8 Reactivation
David C Yao, MD, PhD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Paolo Caimi, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Hillard M. Lazarus, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Brenda Cooper, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Richard Creger, PharmD, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Basem M. William, MD, MRCP(UK), University Hospitals Seidman Cancer Center and Case Western Reserve University;
Merle Kolk, University Hospitals Seidman Cancer Center and Case Western Reserve University;
Marcos J. G. de Lima, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University
![[Visit Client Website]](images/banner.gif)